Abstract
We studied the role and clinical implications of preheparin serum lipoprotein lipase mass( preheparin LPL mass). Among hyperlipidemic patients, preheparin LPL mass in type IIa was almost equal to that of normal control, but those in type IV and IIb were significantly lower. In non-insulin dependent diabetes mellitus, preheparin LPL mass was significantly lower than controls. HbAlc was negatively correlated with preheparin LPL mass. An insulin-sensitizer troglitazone administration to noninsulindependent diabetes mellitus patients enhanced preheparin LPL mass and HDL-cholesterol, accompanying with decreases in HbAlc and triglycerides. Bezafibrate administration to type IIb or IV patients decreased triglyceride and increased HDL-cholesterol and preheparin LPL mass also.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
